CClinicalTrials.gg
Enrolling by invitationNCT07247760Updated Nov 25, 2025

PATIENT SATISFACTION AND MASKING OF WHITE SPOT LESIONS AFTER HOME WHITENING WITH 10% CARBAMIDE PEROXIDE

An interventional study of Whitening treatment with 10% carbamide peroxide on teeth with white spot lesions in White Spot Lesions, sponsored by Universidad Rey Juan Carlos. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Universidad Rey Juan Carlos · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as enrolling by invitation.
Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The clinical trial aims to evaluate patient satisfaction and the efficacy of home whitening with 10% carbamide peroxide in masking white spot lesions, as well as the presence of sensitivity and gingival irritation.

Read the detailed description

The clinical trial aims to evaluate patient satisfaction and the efficacy of home whitening with 10% carbamide peroxide in masking white spot lesions, as well as the presence of sensitivity and gingival irritation. Patients with at least one white spot due to enamel development defects in any of the anterior teeth will be selected, up to a minimum of 67 lesions. An initial characterisation of the white spot lesions will be performed using different standardised photographs with cross-polarisation filters, fluorescence and transillumination. In addition, mapping will be performed using a spectrophotometer to record the L*a*b* parameters in the lesions and surrounding tissue, and patients will initially respond to a survey on their satisfaction with the lesions (VAS scale) and their impact on psychosocial well-being and oral health-related quality of life (PIDAQ and OHIP-14, respectively). Patients classified for the study will be whitened with 10% carbamide peroxide for 3 hours a day for 4 weeks, or until the desaturation obtained is to their liking, or until the CIELAB L* parameter measurements indicate stabilisation of brightness using the spectrophotometer. During treatment, the presence of sensitivity and irritation will be recorded using a VAS scale. Patients will be reviewed 4 weeks after the end of treatment and will respond again to the questionnaire on satisfaction, psychosocial impact of dental aesthetics and oral quality of life (PIDAQ and OHIP-14), and the lesions will be characterised again. The data obtained on satisfaction, PIDAQ and OHIP-14 surveys will be statistically analysed, as will the colour difference between the lesions and the surrounding tissue enamel at the end of treatment.

02

Conditions studied

  • White Spot Lesions

Keywords

  • white spot
  • bleaching
  • satisfaction
  • gingival irritation
  • sensitivity
03

In context

Personal Satisfaction

126 studies on the registry are indexed under Personal Satisfaction; 50 are open to participants now.

This study's planned enrollment of 67 is below the median of 90 across 104 interventional studies indexed under Personal Satisfaction.

Browse Personal Satisfaction studies →

Lead sponsor

Universidad Rey Juan Carlos is the lead sponsor of 111 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Be over 18 years of age.
  • Have white spots on teeth between 1.3 and 2.3 or between 3.3 and 4.3.
  • No previous dental treatment on teeth affected by hypomineralisation lesions.
  • No active caries lesions at any ICDAS II stage on the anterior teeth.
  • Patients with satisfactory oral hygiene and periodontal health, who are not undergoing periodontal maintenance and who do not use chlorhexidine mouthwashes. Patients with recessions without sensitivity are included.

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously undergone whitening treatment (less than 5 years ago).
  • Patients undergoing orthodontic treatment.
  • Patients with a history of trauma to the front teeth.
  • Patients with endodontically treated anterior teeth.
  • Pregnant or breastfeeding patients.
  • Patients who smoke.
  • Patients with periodontal disease.
  • Patients with poor oral hygiene.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (estimated)

Study arms

  • Experimental
    Whitening treatment for teeth with white spot lesions

    Whitening treatment with 10% carbamide peroxide on teeth with white spot lesions. Assess patient satisfaction with the masking of white spot lesions and the occurrence of tooth sensitivity and gingival irritation.

    Other: Whitening treatment with 10% carbamide peroxide on teeth with white spot lesions

Interventions

  • OtherWhitening treatment with 10% carbamide peroxide on teeth with white spot lesions

    Whitening treatment with 10% carbamide peroxide on teeth with white spot lesions. Assess patient satisfaction with the masking of white spot lesions and the occurrence of tooth sensitivity and gingival irritation.

06

What researchers measure

Primary outcomes

  1. Degree of satisfaction with whitening on white spot lesions

    The patient will answer questions using the PIDAQ questionnaire to assess whether they consider their white spot lesions to be masked after the whitening treatment.

    Time frame: 2 weeks

Secondary outcomes

  1. Effectiveness of masking white spot lesions

    The lesions will be characterised as described above at 4 weeks and one month after the end of the whitening treatment. If the whitening treatment is prolonged, this will also be done at the end of the treatment. The effectiveness of masking will be determined by the colour difference between the lesions and the surrounding tissue using the CIELAB formula (De L'Eclairage, 1978): ∆Eab = \[(∆L\*)2 + (∆a\*)2 + (∆b\*)2\]1/2. By definition, a tooth is considered masked when the colour difference (ΔEab) between the lesions and the surrounding healthy enamel is ΔEab ≤3.7, and unmasked if ΔEab \> 3.7. A colour difference below the acceptability threshold of 3.7 was chosen as an indicator of masking. In addition, the colour change will also be calculated using the CIEDE 2000 formula: Additionally, the CIEDE2000 formula will be applied; ∆E00 = \[(ΔL/kLSL)2 + (ΔC/kCSC)2 + (ΔH/kHSH)2 + RT(ΔC\*ΔH/SC\*SH)\]1/2 and the whiteness index (WI)

    Time frame: 2 weeks

  2. EVALUATION OF DENTAL SENSITIVITY

    We will assess sensitivity and intensity using a visual analogue scale (VAS) from 0 to 10. Each patient will be given a diary covering the two weeks between appointments, which they will have to fill in daily. Zero will represent 'no pain' on the visual analogue scale and ten will represent 'severe pain'. Patients will be asked to record the worst result once a day, even if there has been no pain, marking with a vertical line the value corresponding to the intensity of their tooth sensitivity, which will then be measured in centimetres. If the patient marks any value above zero, it will be interpreted as tooth sensitivity. In cases of severe sensitivity, desensitising agents or analgesics/anti-inflammatories will be dispensed.

    Time frame: 2 weeks

  3. EVALUATION OF GINGIVAL IRRITATION

    We will assess gingival irritation and the intensity of said irritation using a visual analogue scale (VAS) from 0 to 10 by means of a diary that will be provided together with the dental sensitivity diary, which the patient will fill in the same way, with zero being 'no gingival irritation' and ten being 'severe irritation'. Patients will be asked to record the worst result once a day, even if there has been no irritation, marking with a vertical line the value corresponding to the intensity of gingival irritation, which will then be measured in cm.

    Time frame: 2 weeks

  4. EVALUATION OF THE APPEARANCE OF NEW SPOTS

    We will assess the appearance of new lesions during treatment using a visual analogue scale (VAS) from 0 to 10 in a diary that will be provided along with the tooth sensitivity diary, which the patient will fill out in the same way, with zero being 'very dissatisfied' and ten being 'very satisfied'. Patients will be asked to record the worst result once a day by marking with a vertical line the value corresponding to the intensity of gingival irritation, which will then be measured in centimetres.

    Time frame: 2 weeks

07

Study locations

1 site
  • Universidad Rey Juan Carlos
    Alcorcón, Madrid 28922, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07247760
Lead sponsor
Universidad Rey Juan Carlos
Responsible party
Isabel Giráldez de Luis (PhD DDS, Universidad Rey Juan Carlos) — Principal investigator
First posted
Nov 25, 2025
Start date
Oct 27, 2025
Primary completion
Mar 2, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Nov 25, 2025

Study contacts

Mª VICTORIA FUENTES, PhD Proffesor
study director · Universidad Rey Juan Carlos

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion